Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors

Inclusion Criteria: * Voluntary written informed consent form. * Histologically or cytologically confirmed advanced malignant solid tumors. * Measurable or non-measurable disease following (RECIST) * Age ≥ 18 years. * Life expectancy ≥ 3 months. * Performance status ECOG ≤ 2. * Recovery from any drug-related adverse events (AEs) derived from previous treatments. * Appropriate bone marrow, liver and renal function. * Left ventricular ejection fraction (LVEF) within normal limits for the institution. * Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for three months after discontinuation of treatment. Exclusion Criteria: * Prior therapy with PM02734. * Pregnant or lactating women. * Less than four weeks from radiation therapy. * Evidence of progressive central nervous system (CNS) metastases. or any symptomatic brain or leptomeningeal metastases. * Other relevant diseases or adverse clinical conditions. * Any other major illness that, in the Investigator's judgment. * Limitation of the patient's ability to comply with the treatment or to follow-up at a participating protocol. * Ingestion of potent cytochrome CYP3A4 inhibitors. * Treatment with any investigational product in the 30-day period prior to the first infusion. * Known hypersensitivity to any component of PM02734 or erlotinib.